BR9916833A - Derivados de epotilona e seu uso como agentes antitumor - Google Patents
Derivados de epotilona e seu uso como agentes antitumorInfo
- Publication number
- BR9916833A BR9916833A BR9916833-2A BR9916833A BR9916833A BR 9916833 A BR9916833 A BR 9916833A BR 9916833 A BR9916833 A BR 9916833A BR 9916833 A BR9916833 A BR 9916833A
- Authority
- BR
- Brazil
- Prior art keywords
- antitumor agents
- epothilone derivatives
- epothilone
- derivatives
- antitumor
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003883 epothilone derivatives Chemical class 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Silicon Polymers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH253098 | 1998-12-22 | ||
| PCT/EP1999/010129 WO2000037473A1 (en) | 1998-12-22 | 1999-12-20 | Epothilone derivatives and their use as antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9916833A true BR9916833A (pt) | 2001-09-25 |
Family
ID=4235876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9916833-2A BR9916833A (pt) | 1998-12-22 | 1999-12-20 | Derivados de epotilona e seu uso como agentes antitumor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6387927B1 (https=) |
| EP (1) | EP1140944B1 (https=) |
| JP (1) | JP2002533346A (https=) |
| CN (1) | CN1122668C (https=) |
| AT (1) | ATE248175T1 (https=) |
| AU (1) | AU2795000A (https=) |
| BR (1) | BR9916833A (https=) |
| CA (1) | CA2352505C (https=) |
| DE (1) | DE69910831T2 (https=) |
| ES (1) | ES2207983T3 (https=) |
| PT (1) | PT1140944E (https=) |
| WO (1) | WO2000037473A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1186606T4 (da) | 1995-11-17 | 2011-12-05 | Biotechnolog Forschung Gmbh | Epothilonderivater, deres fremstilling og anvendelse |
| DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| AU2002230386A1 (en) * | 2000-09-25 | 2002-04-29 | Kosan Biosciences, Inc. | Sixteen-membered macrolide compounds |
| HU229349B1 (en) | 2001-01-25 | 2013-11-28 | Bristol Myers Squibb Co | Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer |
| IL156580A0 (en) | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| BR0207487A (pt) | 2001-02-20 | 2004-08-10 | Brystol Myers Squibb Company | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona |
| PL363363A1 (en) | 2001-02-20 | 2004-11-15 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| SK287334B6 (sk) * | 2001-03-19 | 2010-07-07 | Novartis Ag | Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie |
| MXPA03010909A (es) | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Derivados de epotilona. |
| WO2003031414A1 (en) * | 2001-10-03 | 2003-04-17 | Nippon Soda Co.,Ltd. | Novel heterocyclic compound and anti-inflammatory agent |
| AU2003235761A1 (en) * | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
| AU2003218107A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| SI1483251T1 (sl) | 2002-03-12 | 2010-03-31 | Bristol Myers Squibb Co | C cian epotilonski derivati |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| DE60330407D1 (de) | 2002-08-23 | 2010-01-14 | Sloan Kettering Inst Cancer | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| PT1537116E (pt) | 2002-09-04 | 2010-09-03 | Schering Corp | Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas |
| GB0221312D0 (en) * | 2002-09-13 | 2002-10-23 | Novartis Ag | Organic compounds |
| BRPI0314133A8 (pt) | 2002-09-23 | 2017-09-19 | Bristol Myers Squibb Co | Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona |
| WO2004034970A2 (en) * | 2002-09-27 | 2004-04-29 | Nereus Pharmaceuticals, Inc. | Macrocyclic lactams |
| DE10256982A1 (de) * | 2002-12-05 | 2004-06-24 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung |
| US20040146632A1 (en) * | 2003-01-23 | 2004-07-29 | Cristina Sayman | Effective multi-component penetrating and flavoring marinade |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| GB0405898D0 (en) * | 2004-03-16 | 2004-04-21 | Novartis Ag | Organic compounds |
| US7122700B2 (en) * | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| EP1845096A1 (en) * | 2006-03-27 | 2007-10-17 | ETH Zürich | 12-Aza-epothilones, process for their preparation and their use as antiproliferative agents |
| US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
| AU2007250443B2 (en) | 2006-05-16 | 2013-06-13 | Pharmascience Inc. | IAP BIR domain binding compounds |
| DE102007016046A1 (de) * | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
| EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| CN101519404B (zh) * | 2008-02-29 | 2016-01-20 | 唐莉 | 15环噻酮衍生物及其制备方法与应用 |
| WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| US9764038B2 (en) | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
| US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
-
1999
- 1999-12-20 CN CN99815116A patent/CN1122668C/zh not_active Expired - Fee Related
- 1999-12-20 ES ES99969216T patent/ES2207983T3/es not_active Expired - Lifetime
- 1999-12-20 BR BR9916833-2A patent/BR9916833A/pt not_active Application Discontinuation
- 1999-12-20 AU AU27950/00A patent/AU2795000A/en not_active Abandoned
- 1999-12-20 DE DE69910831T patent/DE69910831T2/de not_active Expired - Lifetime
- 1999-12-20 JP JP2000589543A patent/JP2002533346A/ja active Pending
- 1999-12-20 WO PCT/EP1999/010129 patent/WO2000037473A1/en not_active Ceased
- 1999-12-20 PT PT99969216T patent/PT1140944E/pt unknown
- 1999-12-20 AT AT99969216T patent/ATE248175T1/de not_active IP Right Cessation
- 1999-12-20 EP EP99969216A patent/EP1140944B1/en not_active Expired - Lifetime
- 1999-12-20 CA CA002352505A patent/CA2352505C/en not_active Expired - Fee Related
-
2001
- 2001-06-01 US US09/871,860 patent/US6387927B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000037473A1 (en) | 2000-06-29 |
| US6387927B1 (en) | 2002-05-14 |
| DE69910831T2 (de) | 2004-07-15 |
| JP2002533346A (ja) | 2002-10-08 |
| CA2352505C (en) | 2009-04-07 |
| ATE248175T1 (de) | 2003-09-15 |
| ES2207983T3 (es) | 2004-06-01 |
| DE69910831D1 (de) | 2003-10-02 |
| AU2795000A (en) | 2000-07-12 |
| EP1140944A1 (en) | 2001-10-10 |
| CA2352505A1 (en) | 2000-06-29 |
| CN1122668C (zh) | 2003-10-01 |
| CN1332742A (zh) | 2002-01-23 |
| EP1140944B1 (en) | 2003-08-27 |
| PT1140944E (pt) | 2004-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9916833A (pt) | Derivados de epotilona e seu uso como agentes antitumor | |
| UY28623A1 (es) | Derivados de pirazol y usos de los mismos | |
| TR200200820T2 (tr) | Benzodiazepin türevleri,bunların üretimi ve kullanımları | |
| BR0108715A (pt) | Compostos de 3,4-diidro-1h-pirimido[4,5-d]-pirimidin-2-ona 1,5-dissubstituìdos e seu uso no tratamento de doenças mediadas pela cinase csbp/p38 | |
| MX9700557A (es) | Dihidrobenzofuranos. | |
| PT998460E (pt) | Novos derivados de tetrazole | |
| ECSP045255A (es) | Cumarinas utiles como biomarcadores | |
| HRP20080664A2 (hr) | Supstituirani piridinski herbicidi | |
| BR0107770A (pt) | Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas | |
| BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
| ATE515262T1 (de) | Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel | |
| DK1042319T3 (da) | Dihydrobenzofuraner | |
| PT1086096E (pt) | Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4 | |
| AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| AR025224A1 (es) | Amida y guanidina oxazolidinona n-sustituida antibacteriana y metodos de uso de la misma | |
| ATE251162T1 (de) | Triazolo(4,5-d)pyrimidin-verbindungen | |
| BRPI0412446A (pt) | compostos de silicio e seu uso | |
| DE50010403D1 (de) | Polycyclische thiazol-systeme und ihre verwendung als anorektika | |
| BRPI0415038A (pt) | derivados de imidazo (4,5-b) piridina como inibidores sem ser da sintase que podem ser induzidos | |
| BR0313400A (pt) | N-aril-2-oxazolidinonas e seus derivados | |
| PT1244614E (pt) | Inibidores de triptase | |
| BRPI0412360A (pt) | compostos de organossilìcio e seu uso | |
| ES2159489A1 (es) | Nuevos derivados de imidazol con actividad antiinflamatoria. | |
| BRPI0413744A (pt) | n-aril-2-ciano-oxazolidinonas e seus derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 11 E 13 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |